Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
Date:8/30/2010

ategy. We are now working towards an official response to the EMA Day 120 questions, due by the end of 2010.

As of today we remain confident in the approvability of Glybera(R). Our assessment is based on the following:

- Our response to the EMA does not require further clinical trials with additional new to be treated patients. We expect to be able to formulate our response satisfactorily by submitting data and further analyses from already treated patients. - More, highly relevant, data from our last clinical trial CT-AMT-011-02 AMT strongly suggest that Glybera's effects are lasting (one year) via a mechanism that causes clearance of chylomicrons, the fat carrying particles which are responsible for pancreatitis in LPLD patients. - Overall we have developed a clear response strategy, which, if executed with no unforeseen adverse events or delays, should allow us to remain on track for a positive EMA decision in the middle of 2011.

Hemophilia B

Further to their 2009 agreement to co-develop a vector-gene combination for the treatment of Hemophilia B, AMT and St. Jude Children's Research Hospital in the USA have successfully transferred Factor IX to AMT's manufacturing platform and have demonstrated proof of concept in animals in 2010. The multicenter, dose escalation study with this vector-gene combination began in March, 2010 at University College London Hospital in the United Kingdom guided by Prof. Amit Nathwani. The first patient has been dosed successfully and demonstrated good results both in terms of clinical benefit and side effects. Further enrolment of patients is expected in the second half of 2010.

Duchenne Muscular Dystrophy

In support of its program to treat Duchenne Muscular Dystrophy, AMT received an investment credit from SenterNovem (now Agentschap.nl), the Dutch government innovation agency, in January 2010. The credit comprises a loan covering 35% of the costs of the project through to 2013 with
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
2. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
6. Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine
7. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
8. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
9. VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
10. BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth
11. Brain-like computing on an organic molecular layer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... PALO ALTO, Calif., Oct. 26 Telik, Inc. (Nasdaq: ... HCl), the company,s lead therapeutic product candidate, has been ... of "The Top 10 Most Interesting Oncology Projects to ... to senior executives in the pharmaceutical, biotechnology, and medical ...
... Genomic Health , Inc. (Nasdaq: GHDX ) ... webcast on Monday, November 8 at 4:30 p.m. Eastern Time to ... will follow the release of the third quarter financial results after ... To access the live conference call on November 8 ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) is scheduled ... the Waldorf-Astoria Hotel in New York City on Tuesday, ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) (Logo: ... presentation will be accessible on the Company,s website at ...
Cached Biology Technology:TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 2TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 3Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 2Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... may have found a way to dramatically slow organ ... That's the promising implication of an animal study carried ... Birmingham (UAB) and the University of Florida (UF) published ... National Academy of Sciences. , The research team reported ...
... A drug first used to reduce the risk of stomach ... alternative to surgery after miscarriage, according to a study by ... Development of the National Institutes of Health and other research ... New England Journal of Medicine. , The drug, misoprostol, has ...
... protein design by a University of Houston professor will ... Nano Summit Research Conference July 28. , Kurt L. ... UH, will give a presentation at 11 a.m. on ... by the Nanotechnology Foundation of Texas, the 2005 Nano ...
Cached Biology News:Discoveries by UAB and Florida scientists may help transplanted organs survive longer 2Drug Offers Alternative to Surgical Treatment After Miscarriage 2Drug Offers Alternative to Surgical Treatment After Miscarriage 3Drug Offers Alternative to Surgical Treatment After Miscarriage 4Disease diagnosis, bioengineering covered at state nano summit 2
... Kit provides a fast and simple procedure for ... buffer exchange, and for removing different types of ... on spin-column chromatography using Norgens patented protein resin ... 2 , NaCl, KCl, CaCl 2 , LiCl, ...
... Surveyor software provides local instrument control ... HPLC Systems. The software operates on ... Windows Pocket PC 2002 O/S and ... directly to their Surveyor quaternary gradient ...
... Kit is a very sensitive immunohistochemical tool ... containing both anti-von Willebrand Factor and anti-CD31 ... variety of species. This AP kit provides ... of frozen and paraffin-embedded sections in human ...
... and MDS Sciex present the 4000 ... performance hybrid triple quadrupole/linear ion trap ... drug development or proteomics researcher. Innovative ... the leaders in mass spectrometry brings ...
Biology Products: